Clareo Health | A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
A two arm study (1 Active, 1 Active control) to compare the incidence, progression and severity of chronic renal allograft failure in at-risk patients who are converted from cyclosporine-based to tacrolimus-based immunosuppression to patients who remain on cyclosporine-based therapy
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has been on cyclosporine-based immunosuppression regimen since the transplant
Patient has at least one pre-defined risk factor for chronic allograft failure
You may not be if
Patient is dialysis dependent
Patient is recipient of a solid organ transplant other than the kidney
